Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

OKYO Pharma Says OK-101 Achieves Statistical Significance For Multiple Signs And Symptoms Of Dry Eye Disease Including Ocular Pain Relief In Its First-in-Human Phase 2 Trial Of OK-101

Author: Benzinga Newsdesk | March 22, 2024 07:03am

Posted In: OKYO